RxDoctor Payments Data

David Miloy, MD

Internal Medicine · Kerrville, TXNPI 1912935990

Payments from drug & device makers

$2,907in general payments, 2019–2025

Across 100 payments — averaging $29.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merz North America, Inc.$1K
  • Amgen$496
  • Radius Health, Inc.$247
  • AbbVie$129
  • GSK$117
  • Astellas Pharma US Inc$117
  • plus $355 from 10 others

What the payments were for

  • Food & beverage$2,907100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,907 in reported general payments places this provider in the 80th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$186,131
Medicare patients
278
Services billed
3,414

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide126$146,146
OzempicSemaglutide74$105,844
EliquisApixaban97$101,049
FarxigaDapagliflozin Propanediol38$43,990
Trelegy ElliptaFluticasone/Umeclidin/Vilanter33$34,191
MyrbetriqMirabegron29$25,869
JanuviaSitagliptin Phosphate13$20,285
JardianceEmpagliflozin13$16,754
XareltoRivaroxaban12$13,922
TrulicityDulaglutide14$13,465
Breo ElliptaFluticasone/Vilanterol27$12,124
PremarinEstrogens, Conjugated12$6,325
SymbicortBudesonide/Formoterol Fumarate12$4,477
Atorvastatin Calcium365$3,887
Gabapentin177$3,602

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$102$159,610140 claims
PfizerEliquis, Premarin, Paxlovid$41$110,231128 claims
Novo NordiskOzempic$16$105,84474 claims
AstraZenecaFarxiga, Symbicort$13$48,46750 claims
GSKTrelegy Ellipta, Breo Ellipta$117$46,31560 claims
Astellas Pharma US IncMyrbetriq$117$25,86929 claims
Johnson & JohnsonXarelto$34$13,92212 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$14$2,637241 claims
AbbVieSynthroid$129$2,31638 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Kerrville

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →